Medtronic announces milestone reached in clinical program for IN.PACT

theflyonthewall.com

Medtronic announced that enough patients have been enrolled in its clinical studies of the IN.PACT Admiral drug-eluting balloon to support the company's U.S. regulatory approval submission of the novel angioplasty device, which is designed to treat atherosclerotic lesions in the superficial femoral artery. In a related development, Medtronic also announced that it plans to submit the first module of the pre-market approval application for the IN.PACT Admiral drug-eluting balloon to the FDA over the summer.

Rates

View Comments